这篇文章概述了早期非小细胞肺癌（NSCLC）免疫疗法的进展，特别是在围手术期使用免疫检查点抑制剂（ICIs）。文章讨论了新辅助免疫疗法的益处，包括病理完全缓解（pCR）率的显著提高和无事件生存期的延长。然而，它也强调了当前生物标志物在预测治疗反应方面的局限性。为了克服这些挑战，文章提出了一种整合多组学的方法，结合了肿瘤内在因素、免疫微环境和全身性生物标志物，旨在实现更精确的免疫疗法。此外，该综述还展望了未来的方向，包括实时监测和适应性治疗策略，以优化患者预后。References: Vaccaro A, Rahal Z, Kadara H, et al. A Roadmap to Precision Immunotherapy for Early-Stage Non–Small Cell Lung Cancer[J]. Cancer Discovery, 2025, 15(5): 884-889.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Trump $82 Million Bond Spree, Brazil Tariffs 'Too High,' More
16 Nov 2025
Bloomberg News Now
Ex-Fed Gov Resigned After Rules Violations, Trump Buys $82 Mil of Bonds, More
16 Nov 2025
Bloomberg News Now
THIS TRUMP INTERVIEW WAS INSANE!
16 Nov 2025
HasanAbi
Epstein Emails and Trump's Alleged Involvement
15 Nov 2025
Conspiracy Theories Exploring The Unseen
New Epstein Emails Directly Implicate Trump - H3 Show #211
15 Nov 2025
H3 Podcast
Trump Humiliates Himself on FOX as They Call Him Out
15 Nov 2025
IHIP News